Drugs / SQ tree SLIT-tablet
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02481856 | Jun 2015 → Apr 2016 | allergic disease | ALK-Abelló A/S | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | ALK-Abelló A/S | Results ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies alk.net ↗
ALK presented new data from two paediatric phase 3 clinical trials evaluating SQ sublingual immunotherapy (SLIT) tablets in house dust mite (HDM) and tree pollen respiratory allergy. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-03 | ALK-Abelló A/S | ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies alk.net ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SQ tree SLIT-tablet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02481856 ↗ |